文献速递免疫规划卫生政策与健康促进

南非乙型肝炎出生剂量疫苗的成本效果:数学建模分析

Cost-effectiveness of the hepatitis B birth-dose vaccine in South Africa: a mathematical modelling analysis.
PubMed 文献 · Lancet Glob Health · 2026-09-02

2022年南非乙型肝炎患病率估计为4·7-6·0%。结果显示,选择性PAP加普遍HepB-BD政策避免疾病负担最大,在支付意愿阈值0·5倍人均GDP(ZAR 57 281)下最具成本效果。

要点

  • 当前南非选择性HepB-BD政策每避免一例垂直传播慢性乙肝感染需接种6人(95%UI 3-15)。
  • 普遍HepB-BD-only政策需接种462人(95%UI 223-1479),选择性PAP加普遍HepB-BD政策需77人(95%UI 38-240)。
  • 选择性PAP加普遍HepB-BD政策项目成本最高,但避免疾病负担最大且最具成本效果。

核心结论

  • 研究结果支持在南非当前乙肝病毒传播消除工作中实施普遍HepB-BD政策。

研究设计与样本

  • 使用已验证的传播、疾病进展和死亡模型模拟南非持续乙肝流行。
  • 成本以2024年ZAR(经消费者价格指数调整)报告,结果按每年3%贴现。

主要发现

  • 当前政策每避免一例垂直获得性慢性乙肝感染的需接种人数为6(95%不确定性区间3-15)。
  • 普遍HepB-BD-only政策需接种人数为462(95%UI 223-1479)。
  • 选择性PAP加普遍HepB-BD政策需接种人数为77(95%UI 38-240)。
  • 选择性PAP加普遍HepB-BD政策项目成本最高但避免疾病负担最大,在支付意愿阈值0·5倍人均GDP(ZAR 57 281)下最具成本效果。

关键数值与推荐

  • 支付意愿阈值为0·5倍人均GDP,即ZAR 57 281。
  • 当前政策需接种人数6(95%UI 3-15),普遍HepB-BD-only政策462(95%UI 223-1479),选择性PAP加普遍HepB-BD政策77(95%UI 38-240)。

临床怎么用

  • 在南非应实施普遍HepB-BD政策,并与选择性PAP及当前乙肝消除努力结合。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In 2022, South Africa had an estimated hepatitis B prevalence of 4·7-6·0%. In an effort to eliminate viral hepatitis as a public health threat, a targeted (ie, selective) hepatitis B birth-dose vaccination (HepB-BD) policy was introduced in 2023. Under this policy, only infants born to mothers with confirmed hepatitis B positivity are eligible for HepB-BD, which is given in addition to peripartum antiviral prophylaxis (PAP) for mothers from the second or third trimester of pregnancy. This policy differs from the WHO recommendation that all newborns should receive a HepB-BD vaccine (ie, a universal HepB-BD policy). We aimed to assess comparative costs and benefits of this and alternate policies in South Africa. METHODS: A validated model of transmission, disease progression, and mortality was used to simulate the ongoing hepatitis B epidemic in South Africa. We projected outcomes from the current South African policy (ie, selective PAP plus selective HepB-BD), a universal HepB-BD-only policy, and the WHO-endorsed selective PAP plus universal HepB-BD policy. Health and economic impacts were compared with a baseline of no HepB-BD coverage, over a 2025-100 time horizon. Costs were reported in consumer price index-adjusted 2024 ZAR and outcomes discounted at 3% per annum. FINDINGS: The current South African HepB-BD policy required fewer vaccinations per outcome averted, with the number needed to vaccinate per vertically acquired chronic hepatitis B infection averted found to be six (95% uncertainty interval 3-15), compared with 462 (223-1479) under a universal HepB-BD-only policy or 77 (38-240) under a selective PAP plus universal HepB-BD policy. Despite incurring the greatest programmatic costs, a selective PAP plus universal HepB-BD policy averted the greatest disease burden and was modelled to be the most cost-effective option at a willingness-to-pay threshold of 0·5 × per-capita gross domestic product (ZAR 57 281). INTERPRETATION: Our findings support implementation of a universal HepB-BD policy alongside South Africa's current hepatitis B viral transmission elimination efforts. FUNDING: Vaccine Impact Modelling Consortium.

来源:Lancet Glob Health,查看原文。版权归原作者所有。

引用

  1. Seaman C, Bailie C, Spearman CW, et al. Cost-effectiveness of the hepatitis B birth-dose vaccine in South Africa: a mathematical modelling analysis. Lancet Glob Health. 2026. PMID: 42685764. doi:10.1016/j.langlo.2026.103975

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。